Preclinical evaluation of holmium‐166 labeled anti‐VEGF‐A(Bevacizumab). (5th June 2013)

• Record Type: Journal Article
• Authors: Khorami‐Moghadam, Alireza; Bolouri, Bahram; Jalilian, Amir Reza; Bahrami‐Samani, Nariman Mosafa, Ali; Mazidi, Seyed Mohammad; Alirezapour, Behrouz
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 56:Number 8(2013)
• Page Start: 365
• Page End: 369
• Publication Date: 2013-06-05
• Subjects: Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.3044
• Languages: English
• ISSNs: 0362-4803

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Radiolabeled antiangiogenic monoclonal antibodies are potential agents for targeted therapy in specific types of malignancies. In this study, ¹⁶⁶Ho‐DOTA‐Bevacizumab was used in biodistribution studies using single‐photon emission computed tomography (SPECT) to acquire dosimetric aspects of the radiolabeled antibody in mice. The liver toxicity of the radiolabeled antibody was also determined using serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase and alkaline phosphatase assay 2–7 days post‐injection.</p> <p>The SPECT biodistribution demonstrated a similar pattern as the other radiolabeled anti‐vascular endothelial growth factor A (VEGF‐A) immunoconjugates.¹⁶⁶Ho‐DOTA‐Bevacizumab was revealed as a potential compound for therapy/imaging of VEGF‐A expression in oncology. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p> </abstract>